CXCR2 and breast carcinoma: These results are also consistent with previous studies in which Bandyopadhyay et al. (2010); Sharma et al. (2013a) showed an increase in CXCR2 and/or TGF-β levels in aggressive breast cancer cells post treatment with doxorubicin, whereas the targeting of either of them was able to increase the response of cancer cells to doxorubicin.